Key Highlights:

• Invion continues advancing the development of its Photosoft™ platform across multiple disease areas.

• Recent updates included a new research collaboration targeting eye diseases and continued clinical progress.

• The company remains focused on expanding the applications of its photodynamic therapy technology.

• Investors continue monitoring clinical studies, research partnerships and regulatory milestones.

Invion Ltd (ASX: IVX) is a clinical-stage biotechnology company developing its proprietary Photosoft™ platform for the treatment of cancer, infectious diseases and other medical conditions. The company's research focuses on photodynamic therapy (PDT), which combines a photosensitising compound with light to target diseased cells while minimising damage to surrounding healthy tissue.

As clinical development progresses, investors continue monitoring research outcomes, strategic collaborations and regulatory milestones that could influence the company's future direction.

Recent Update Highlights Clinical Progress

Invion recently entered into a strategic collaboration with SANGMYUNG Innovation Co., Ltd to evaluate the potential of the Photosoft™ platform for treating wet age-related macular degeneration and other ophthalmic conditions. The collaboration expands the potential applications of the technology beyond oncology while allowing preclinical research to be undertaken through the partnership.

The company has also continued progressing clinical studies involving Photosoft™ across multiple cancer indications while strengthening its scientific and clinical advisory capabilities.

Key Business Drivers

Photosoft™ Platform Development

The company's primary focus remains advancing its proprietary Photosoft™ technology across oncology, ophthalmology and infectious disease applications.

Clinical Development

Progress in clinical and preclinical studies will remain an important factor in evaluating the potential of the company's therapeutic platform.

Research Partnerships

Collaborations with research institutions and commercial partners support technology development and broaden opportunities for future applications.

Intellectual Property Portfolio

Invion continues expanding and protecting its intellectual property, supporting the long-term development of its drug pipeline.

Latest Business Developments

Invion continues progressing research programmes while evaluating additional applications for its Photosoft™ technology. The company has also strengthened its clinical advisory team and continues engaging with research partners to support future development activities.

Management remains focused on advancing clinical studies, expanding strategic collaborations and progressing regulatory pathways for its lead technology platform.

Risks Investors Should Consider

As a clinical-stage biotechnology company, Invion faces risks associated with drug development, including clinical trial outcomes, regulatory approvals and commercialisation timelines.

The company may also require additional funding to support ongoing research and development activities. Competition from other biotechnology companies and evolving treatment technologies could also influence future progress.

Outlook

Invion continues advancing the development of its Photosoft™ platform while expanding research into additional therapeutic areas. Clinical trial progress, research collaborations, regulatory developments and future scientific data are expected to remain important areas of investor focus.

Investors will continue monitoring updates as the company progresses its development programmes and evaluates opportunities to broaden the application of its proprietary technology.